Please review the CME information and proceed to the bottom of the page to login and access the activity.
Release Date – March 16, 2009Expiration Date – March 15, 2010
Estimated Time to Complete: 2 hours
Chairperson
Brooks Cash, MD
Associate Professor of Medicine
Uniformed Services University of the Health Sciences
Chief, Gastroenterology Division
National Naval Medical Center
Bethesda, Maryland
Faculty
Louis Kuritzky, MD
Clinical Assistant Professor
Family Medicine Residency Program
University of Florida College of Medicine
Gainesville, Florida
Content Reviewer
Joanne Wilson, MD
Professor of Medicine
Division of Gastroenterology
Duke University Medical Center
Durham, North Carolina
Staff and Content Validation Reviewer Disclosure
The staff involved with this activity and any content validation reviewers of this activity have reported no relevant financial relationships with commercial interests.Resolution of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support of CME, the Duke University School of Medicine implemented mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all persons in a position to control content of this CME activity.Planning Committee/Faculty Disclosure
The following speakers and/or planning committee members have indicated that they have relationships with industry to disclose:- Brooks Cash, MD, has indicated he has consulting agreements with Prometheus Laboratories, Inc.; Salix Pharmaceuticals, Inc.; and Takeda Pharmaceuticals North America, Inc.
- Louis Kuritzky, MD, has indicated he is a member of the advisory board for Takeda Pharmaceuticals North America, Inc.
- Joanne Wilson, MD, has indicated she has received honorarium payments from Prometheus Laboratories, Inc.; Sucampo Pharmaceuticals, Inc.; and Takeda Pharmaceuticals North America, Inc.
- Matt Groesbeck, MPH, CHES (DIME editor), is a DIME employee and has no relationships to disclose.
Unapproved Use Disclosure
Duke School of Medicine requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may/will discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information..Disclaimer
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.Accreditation
The Duke University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Credit Designation
The Duke University School of Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.Instructions on How to Receive Credit
- Review the materials on accreditation information, target audience, learning objectives, and disclosure information
- Complete the entire self-study activity
- Complete the self-assessment and evaluation/claim form. Upon submission of evaluation responses, learners will be required to register for CME credit; CME certificates will automatically be generated upon completion of registration
If you need to obtain an additional copy of your CME certificate, you may do so at http://cme.mc.duke.edu. Click on "Credit Record" and "Official Duke CME Transcript."
Statement of Need
Irritable Bowel Syndrome with Constipation (IBS-C) is a condition that affects a significant portion of the population and leads to reduced quality of life. With unclear etiology and the fact that no single biomarker detects IBS-C, an exclusionary diagnosis of IBS-C can be a challenging process. Increasing awareness among primary care physicians is essential to understanding not only the prevalence of IBS-C in women, but to more closely comprehending the needs and concerns of patients themselves. The purpose of this activity is to improve the knowledge and competence of primary care physicians in the assessment and management of patients living with IBS-C.Target Audience
Primary care clinicians with an interest in improving management of IBS-C.Learning Objectives
At the conclusion of this activity, participants should be able to:- Differentiate IBS-C from other IBS subgroups and from non-IBS disorders
- Identify risk factors and symptoms of irritable bowel syndrome with constipation (IBS-C)
- Describe and evaluate the usefulness of IBS-C guidelines, diagnostic tools, and clinical trials to inform a clinical diagnosis and/or treatment
- Explore barriers to effective patient assessment and education to better diagnosing and managing IBS-C
- Analyze IBS-C interventional strategies, including targeted patient education, prescription, and non-prescription options
Cosponsored by: Duke University School of Medicine and DIME 
